Other disclosuresBSE · 524804
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
01 / The disclosure
What the company shared
Submission of Press Release that is being issued by the Company in connection with receipt of USFDA final approval for Perampanel Tablets 2 mg, 4 mg, 6 mg, 8 mg 10 mg and 12 mg.
Exchange-provided summary Company profile
A question for your research
Read the underlying filing for the complete disclosure and any conditions not included in the exchange summary.
The evidence
Read the source excerpts
PDF text extraction is queued. The summary above comes from the exchange listing.
Source & verificationView the disclosure trail
- Summary method
- Exchange-provided text; no generated financial figures
- Exchange identifier
- 8d1f5be2-e7cc-4e3b-be15-c88fec11768e
- First collected
- 3 Oct 2026, 17:18 IST
- PDF extraction
- pending
You’ve reached the end of this disclosure.